Search

Your search keyword '"Ruiz-Camps, Isabel"' showing total 7 results
Start Over Author "Ruiz-Camps, Isabel" Journal clinical infectious diseases
7 results on '"Ruiz-Camps, Isabel"'

1. Healthcare-Associated Mycobacterium bovis–Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation

Author

Meije, Yolanda, Martínez-Montauti, Joaquín, Caylà, Joan A., Loureiro, Jose, Ortega, Lucía, Clemente, Mercedes, Sanz, Xavier, Ricart, Montserrat, Santomà, María J., Coll, Pere, Seirra, Montserrat, Calsina, Marta, Vaqué, Montserrat, Ruiz-Camps, Isabel, López-Sánchez, Cristina, Montes, Mar, Ayestarán, Ana, Carratalà, Jordi, and Orcau, Àngels

Published
2017

3. Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

Author

Averbuch, Diana, primary, Tridello, Gloria, additional, Hoek, Jennifer, additional, Mikulska, Malgorzata, additional, Akan, Hamdi, additional, Yaňez San Segundo, Lucrecia, additional, Pabst, Thomas, additional, Özçelik, Tülay, additional, Klyasova, Galina, additional, Donnini, Irene, additional, Wu, Depei, additional, Gülbas, Zafer, additional, Zuckerman, Tsila, additional, Botelho de Sousa, Aida, additional, Beguin, Yves, additional, Xhaard, Aliénor, additional, Bachy, Emmanuel, additional, Ljungman, Per, additional, de la Camara, Rafael, additional, Rascon, Jelena, additional, Ruiz Camps, Isabel, additional, Vitek, Antonin, additional, Patriarca, Francesca, additional, Cudillo, Laura, additional, Vrhovac, Radovan, additional, Shaw, Peter J, additional, Wolfs, Tom, additional, O’Brien, Tracey, additional, Avni, Batia, additional, Silling, Gerda, additional, Al Sabty, Firas, additional, Graphakos, Stelios, additional, Sankelo, Marja, additional, Sengeloev, Henrik, additional, Pillai, Srinivas, additional, Matthes, Susanne, additional, Melanthiou, Frederiki, additional, Iacobelli, Simona, additional, Styczynski, Jan, additional, Engelhard, Dan, additional, and Cesaro, Simone, additional

Published
2017
Full Text
View/download PDF

4. Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study.

Author

Willekens, Rein, Puig-Asensio, Mireia, Ruiz-Camps, Isabel, Larrosa, Maria N, González-López, Juan J, Rodríguez-Pardo, Dolors, Fernández-Hidalgo, Nuria, Pigrau, Carles, and Almirante, Benito

Subjects
ACADEMIC medical centers, ALGORITHMS, BACTEREMIA, BLOODBORNE infections, TUBERCULOSIS of the bones, GENERIC drug substitution, LENGTH of stay in hospitals, HOSPITAL admission & discharge, INTRAVENOUS therapy, JOINT tuberculosis, LONGITUDINAL method, ORAL drug administration, SKIN diseases, STAPHYLOCOCCAL diseases, TREATMENT effectiveness, CATHETER-related infections, DISEASE risk factors, LINEZOLID, THERAPEUTICS
Abstract

Background Oral switch to linezolid is a promising alternative to standard parenteral therapy (SPT) in Staphylococcus aureus bacteremia (SAB). Methods We conducted a prospective cohort study of all adult cases of SAB between 2013 and 2017 in a Spanish university hospital. We compared the efficacy, safety, and length of hospital stay of patients receiving SPT and those where SPT was switched to oral linezolid between days 3 and 9 of treatment until completion. We excluded complicated SAB and osteoarticular infections. A k-nearest neighbor algorithm was used for propensity score matching with a 2:1 ratio. Results After propensity score matching, we included 45 patients from the linezolid group and 90 patients from the SPT group. Leading SAB sources were catheter related (49.6%), unknown origin (20.0%), and skin and soft tissue (17.0%). We observed no difference in 90-day relapse between the linezolid group and the SPT group (2.2% vs 4.4% respectively; P =.87). No statistically significant difference was observed in 30-day all-cause mortality between the linezolid group and the SPT group (2.2% vs 13.3%; P =.08). The median length of hospital stay after onset was 8 days in the linezolid group and 19 days in the SPT group (P <.01). No drug-related events leading to discontinuation were noted in the linezolid group. Conclusions Treatment of SAB in selected low-risk patients with an oral switch to linezolid between days 3 and 9 of treatment until completion yielded similar clinical outcomes as SPT, allowing earlier discharge from the hospital. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

5. Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis

Author

Fernández-Ruiz, Mario, primary, Aguado, José María, additional, Almirante, Benito, additional, Lora-Pablos, David, additional, Padilla, Belén, additional, Puig-Asensio, Mireia, additional, Montejo, Miguel, additional, García-Rodríguez, Julio, additional, Pemán, Javier, additional, Ruiz Pérez de Pipaón, Maite, additional, Cuenca-Estrella, Manuel, additional, Muñoz, Patricia, additional, Guinea, Jesús, additional, Paño Pardo, José Ramón, additional, Cerrada, Carlos García, additional, Fortún, Jesús, additional, Martín, Pilar, additional, Gómez, Elia, additional, Ryan, Pablo, additional, Campelo, Carolina, additional, de los Santos Gil, Ignacio, additional, Buendía, Ventura, additional, Gorricho, Beatriz Perez, additional, Alonso, Mercedes, additional, Sanz, Francisca Sanz, additional, Merino, Paloma, additional, Romo, Fernando González, additional, Gorgolas, Miguel, additional, Gadea, Ignacio, additional, Losa, Juan Emilio, additional, Delgado-Iribarren, Alberto, additional, Ramos, Antonio, additional, Romero, Yolanda, additional, Romero, Isabel Sánchez, additional, Zaragoza, Oscar, additional, Rodriguez-Baño, Jesús, additional, Suarez, Ana Isabel, additional, Loza, Ana, additional, Aller García, Ana Isabel, additional, Martín-Mazuelos, Estrella, additional, de Pipaón, Maite Ruiz Pérez, additional, Garnacho, José, additional, Ortiz, Carlos, additional, Chávez, Mónica, additional, Maroto, Fernando L., additional, Salavert, Miguel, additional, Blanquer, José, additional, Navarro, David, additional, Camarena, Juan José, additional, Zaragoza, Rafael, additional, Abril, Vicente, additional, Gimeno, Concepción, additional, Hernáez, Silvia, additional, Ezpeleta, Guillermo, additional, Bereciartua, Elena, additional, Hernández Almaraz, José L., additional, Rivas, Rosa Ana, additional, Ayarza, Rafael, additional, Ma Planes, Ana, additional, Ruiz Camps, Isabel, additional, Mensa, José, additional, Almela, Manel, additional, Gurgui, Mercè, additional, Sánchez-Reus, Ferran, additional, Martinez-Montauti, Joaquin, additional, Sierra, Montserrat, additional, Horcajada, Juan Pablo, additional, Sorli, Luisa, additional, Gómez, Julià, additional, Gené, Amadeu, additional, Urrea, Mireia, additional, Valerio, Maricela, additional, Díaz-Martín, Ana, additional, Puchades, Francesc, additional, and Mularoni, Alessandra, additional

Published
2014
Full Text
View/download PDF

6. Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction–Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial.

Author

María Aguado, José, Vázquez, Lourdes, Fernández-Ruiz, Mario, Villaescusa, Teresa, Ruiz-Camps, Isabel, Barba, Pere, Silva, Jose T., Batlle, Montserrat, Solano, Carlos, Gallardo, David, Heras, Inmaculada, Polo, Marta, Varela, Rosario, Vallejo, Carlos, Olave, Teresa, López-Jiménez, Javier, Rovira, Montserrat, Parody, Rocío, and Cuenca-Estrella, Manuel

Abstract

Background. The benefit of the combination of serum galactomannan (GM) assay and polymerase chain reaction (PCR)–based detection of serum Aspergillus DNA for the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological patients remains unclear. Methods. We performed an open-label, controlled, parallel-group randomized trial in 13 Spanish centers. Adult patients with acute myeloid leukemia and myelodysplastic syndrome on induction therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 ratio) to 1 of 2 arms: “GM-PCR group” (the results of serial serum GM and PCR assays were provided to treating physicians) and “GM group” (only the results of serum GM were informed). Positivity in either assay prompted thoracic computed tomography scan and initiation of antifungal therapy. No antimold prophylaxis was permitted. Results. Overall, 219 patients underwent randomization (105 in the GM-PCR group and 114 in the GM group). The cumulative incidence of “proven” or “probable” IA (primary study outcome) was lower in the GM-PCR group (4.2% vs 13.1%; odds ratio, 0.29 [95% confidence interval, .09–.91]). The median interval from the start of monitoring to the diagnosis of IA was lower in the GM-PCR group (13 vs 20 days; P = .022), as well as the use of empirical antifungal therapy (16.7% vs 29.0%; P = .038). Patients in the GM-PCR group had higher proven or probable IA–free survival (P = .027). Conclusions. A combined monitoring strategy based on serum GM and Aspergillus DNA was associated with an earlier diagnosis and a lower incidence of IA in high-risk hematological patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

7. Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients.

Author

Garcia-Vidal, Carolina, Barba, Pere, Arnan, Montse, Moreno, Asunción, Ruiz-Camps, Isabel, Gudiol, Carlota, Ayats, Josefina, Ort, Guillermo, and Carratalà, Jordi

Subjects
ASPERGILLOSIS diagnosis, H1N1 influenza, ACUTE myeloid leukemia, HEMATOPOIETIC stem cell transplantation, CYTOMEGALOVIRUS diseases
Abstract

We report 5 cases of invasive aspergillosis occurring in severely immunosuppressed patients hospitalized with pandemic influenza A (H1N1). We suggest that infection with influenza A (H1N1) may predispose immunocompromised patients to develop invasive aspergillosis. Physicians should be aware of this potential association to allow early diagnosis and prompt treatment of aspergillosis. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results